Shares of Can Fite Biopharma Ltd (NASDAQ:CANF) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price target of $7.50 for the company and are anticipating that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned Can Fite Biopharma an industry rank of 158 out of 265 based on the ratings given to related companies.
Several equities research analysts recently issued reports on the stock. Maxim Group set a $7.00 target price on shares of Can Fite Biopharma and gave the stock a “buy” rating in a report on Tuesday. HC Wainwright set a $6.00 target price on shares of Can Fite Biopharma and gave the stock a “buy” rating in a report on Thursday, August 10th.
Can Fite Biopharma (NASDAQ CANF) traded down 1.2843% during trading on Tuesday, hitting $1.6525. 52,145 shares of the company’s stock traded hands. The stock has a market cap of $27.40 million and a P/E ratio of 6.6100. The company’s 50 day moving average is $1.70 and its 200-day moving average is $1.77. Can Fite Biopharma has a 12 month low of $1.50 and a 12 month high of $2.67.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.